Drug intelligence / Profile preview

APX701

Development stage: Preclinical
Lead developer: Pyxis Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APX701 is an investigational **anti-SIRPalpha antagonist monoclonal antibody** developed by **Apexigen** for oncology. It is designed to bind **signal regulatory protein alpha**, a myeloid checkpoint receptor involved in the CD47-SIRPalpha axis, with the goal of blocking inhibitory signaling that suppresses macrophage-mediated antitumor immunity. Publicly described information indicates APX701 was in **preclinical development** and was presented at the **AACR 2021** meeting as an early-stage cancer immunotherapy program.

Targets

SIRPA (Signal-regulatory protein alpha)

Beyond the preview

Go deeper on APX701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APX701.

Explore the full profile